you are here: Home News Sun Pharma

Sun Pharma

USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?
Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive
What does the new US tariff salvo mean for Indian pharma?
Buyl Sun Pharma; target of Rs 1960: Motilal Oswal
How Sun Pharma’s diverse business is helping it overcome US FDA curbs on manufacturing plants
Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports
Buy Sun Pharma; target of Rs 1960: Motilal Oswal
Sun Pharma Consolidated June 2025 Net Sales at Rs 13,851.40 crore, up 9.47% Y-o-Y
Sun Pharma shares tumble 4% post-Q1 results; should you buy, sell or hold?
Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices
Sun Pharma Standalone June 2025 Net Sales at Rs 5,601.96 crore, up 24.54% Y-o-Y
Sun Pharma Q1 Preview: Earnings likely to rise on India, specialty strength; margin impact from new launches
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
Sun Pharma shares rise 2% as US patent settlement clears path for Leqselvi launch; Morgan Stanley remains overweight
Aurobindo Pharma, Dr Reddy's, Lupin, other pharma stocks tumble up to 3% amid tariff jitters
Indian pharma companies sit on record cash pile, set sights on acquisitions
Pharma stocks sharply tumble as Donald Trump says 'pharma tariffs coming very soon'; Granules, Lupin, Laurus Labs fall up to 4%
Chart of the Day: How Sun Pharma outperformed Indian market under the incoming MD
Sun Pharma shares sink following eight observations from US FDA, UBS maintains 'buy' call
Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role
Buy Sun Pharma; target of Rs 2000: Motilal Oswal
Sun Pharma Q4 net profit declines 19% to Rs 2,154 crore, firm declares Rs 5.50 dividend
Indian generics likely insulated from Trump's drug pricing order, but Sun Pharma faces pressure
What does Trump’s MFN clause mean for the Indian pharma landscape?
Trump’s drug pricing regulation: How does it impact Indian pharma?

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Sun Pharma

USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?

Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive

What does the new US tariff salvo mean for Indian pharma?

Buyl Sun Pharma; target of Rs 1960: Motilal Oswal

How Sun Pharma’s diverse business is helping it overcome US FDA curbs on manufacturing plants

Pharma stocks fall up to 2% as Trump threatens steep tariffs on drug imports

Buy Sun Pharma; target of Rs 1960: Motilal Oswal

Sun Pharma Consolidated June 2025 Net Sales at Rs 13,851.40 crore, up 9.47% Y-o-Y

Sun Pharma shares tumble 4% post-Q1 results; should you buy, sell or hold?

Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices

Sun Pharma Standalone June 2025 Net Sales at Rs 5,601.96 crore, up 24.54% Y-o-Y

Sun Pharma Q1 Preview: Earnings likely to rise on India, specialty strength; margin impact from new launches

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

Sun Pharma shares rise 2% as US patent settlement clears path for Leqselvi launch; Morgan Stanley remains overweight

Aurobindo Pharma, Dr Reddy's, Lupin, other pharma stocks tumble up to 3% amid tariff jitters

Indian pharma companies sit on record cash pile, set sights on acquisitions

Pharma stocks sharply tumble as Donald Trump says 'pharma tariffs coming very soon'; Granules, Lupin, Laurus Labs fall up to 4%

Chart of the Day: How Sun Pharma outperformed Indian market under the incoming MD

Sun Pharma shares sink following eight observations from US FDA, UBS maintains 'buy' call

Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role

Buy Sun Pharma; target of Rs 2000: Motilal Oswal

Sun Pharma Q4 net profit declines 19% to Rs 2,154 crore, firm declares Rs 5.50 dividend

Indian generics likely insulated from Trump's drug pricing order, but Sun Pharma faces pressure

What does Trump’s MFN clause mean for the Indian pharma landscape?

Trump’s drug pricing regulation: How does it impact Indian pharma?